FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, E	J.C. 20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								00											
Name and Address of Reporting Person* SING GEORGE L				<u>R</u> J	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) 777 OLD	,	irst) LL RIVER ROA		3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022									Officer (give title Other (speci below) below)						
(Street) TARRYTOWN NY 10591					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(City)	(S	tate)	(Zip)											Form filed by More than One Reporting Person					
		Tab	le I - N	on-Deri	vative	Sec	uritie	s Ac	quire	d, Di	sposed (of, or Be	neficia	lly Owned	i				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securiti Transaction Disposed Code (Instr. 8)		Disposed 0	es Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
							Code	Code V Amount		(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock			01/03/	01/03/2022						191	A	\$0.0	0 30,049		D				
Common Stock												750		I		by Spouse			
Common Stock												400		I		y pouse/Cus on			
Common Stock												1,000				y Trust for on			
		Т	able II								posed of converti			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transactior Code (Instr 8)		5. Number of		6. Date Exercis Expiration Dat (Month/Day/Ye		isable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	deriva Secur Benef Owner Follov Repor	ities icially d ving rted action(s)	10. Ownersi Form: Direct (I or Indire (I) (Instr.	Beneficia Ownersh t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option (right to buy)	\$625.6	01/03/2022			A		2,707		(2)		01/03/2032	Common Stock	2,707	\$0.0	2	,707	D		

Explanation of Responses:

- 1. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
- 2. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

/s/**George L. Sing

01/05/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.